Stockscreener 앱 받기
24.92
0.65%
0.16
시간 외 거래:
24.74
-0.18
-0.72%
Moderna Inc 주식(MRNA)의 최신 뉴스
Geode Capital Management LLC Buys 1,420,690 Shares of Moderna, Inc. $MRNA - MarketBeat
Moderna to Present at Upcoming Piper Sandler's 37th Annual Healthcare Conference on December 2, 2025 - The Joplin Globe
Moderna, Inc. $MRNA Stock Position Lifted by Letko Brosseau & Associates Inc. - MarketBeat
SG Americas Securities LLC Purchases 487,734 Shares of Moderna, Inc. $MRNA - MarketBeat
Berenberg Adjusts Price Target on Moderna to $28 From $30, Maintains Hold Rating - MarketScreener
Financial Gravity Companies Inc. Takes Position in Moderna, Inc. $MRNA - MarketBeat
Can Moderna Inc. stock hit record highs againPortfolio Value Report & Real-Time Market Trend Scan - newser.com
Candriam S.C.A. Decreases Stock Position in Moderna, Inc. $MRNA - MarketBeat
Moderna, Inc. $MRNA Shares Sold by Aviva PLC - MarketBeat
How Moderna Inc. stock benefits from tech adoptionOptions Play & Technical Pattern Alert System - newser.com
How strong is Moderna Inc. stock revenue growthJuly 2025 Closing Moves & Technical Analysis for Trade Confirmation - newser.com
How (MRNA) Movements Inform Risk Allocation Models - news.stocktradersdaily.com
Moderna (MRNA) Tops S&P 500 Short Interest List in October - GuruFocus
Mitsubishi UFJ Asset Management Co. Ltd. Reduces Stock Position in Moderna, Inc. $MRNA - MarketBeat
How Moderna Inc. stock performs during Fed tightening cyclesJuly 2025 Catalysts & Safe Capital Preservation Plans - Fundação Cultural do Pará
Resona Asset Management Co. Ltd. Reduces Holdings in Moderna, Inc. $MRNA - MarketBeat
Moderna Opens State-of-the-Art Manufacturing and R&D Facility in the UK - Lohud
Moderna Announces Phase 3 Study of Investigational Cytomegalovirus (CMV) Vaccine Did Not Meet Primary Efficacy Endpoint - York Dispatch
Moderna (MRNA) Shareholders Approve Key Proposals at Special Mee - GuruFocus
Moderna Approves Stock Option Exchange Program - TipRanks
Moderna shareholders approve stock option exchange program for employees By Investing.com - Investing.com South Africa
Moderna shareholders approve stock option exchange program for employees - Investing.com
February 2026 Options Now Available For Moderna (MRNA) - Nasdaq
Moderna (MRNA) Stock Surges Amid Partnership Talks and Strong Q3 Results - GuruFocus
What Is Going On With Moderna Stock? - Forbes
5 Insightful Analyst Questions From Moderna's Q3 Earnings Call - Finviz
CytomX Therapeutics to Present at the Jefferies London Healthcare Conference - GlobeNewswire Inc.
Tobam Purchases 55,542 Shares of Moderna, Inc. $MRNA - MarketBeat
Moderna Highlights Seasonal Flu and H5 Pandemic Flu Candidates at IDWeek 2025 - Las Cruces Sun-News
5 Insightful Analyst Questions From Moderna’s Q3 Earnings Call - Yahoo Finance
Day 5 of Gains Streak for Moderna Stock with 13% Return (vs. -36% YTD) [11/12/2025] - Trefis
Using Ichimoku Cloud for Moderna Inc. technicalsQuarterly Profit Review & Verified Momentum Watchlists - newser.com
Does Moderna Inc. fit your quant trading modelMarket Weekly Review & Weekly Top Stock Performers List - newser.com
Carisma Therapeutics Inc. SEC 10-Q Report - TradingView
Moderna Inc. recovery potential after sell offCEO Change & High Return Trade Opportunity Guides - newser.com
Moderna, Inc. Hits New 52-Week Low at USD 23.04 Amid Declining Sales - Markets Mojo
Moderna (MRNA) today — Nov. 12, 2025: Special shareholder vote on option exchange, fresh institutional filings, and live stock action - ts2.tech
Moderna (MRNA) Stock: Top Analyst Reiterates ‘Market Perform’ Rating Amid Cost-Cutting Efforts - CoinCentral
Campbell & CO Investment Adviser LLC Takes Position in Moderna, Inc. $MRNA - MarketBeat
Moderna, Inc. $MRNA Stock Position Lowered by Bank of New York Mellon Corp - MarketBeat
Acadian Asset Management LLC Purchases 477,072 Shares of Moderna, Inc. $MRNA - MarketBeat
Gilead Sciences, Moderna, Artivion, Tenet Healthcare, and Charles River Laboratories Stocks Trade Up, What You Need To Know - The Globe and Mail
Moderna (MRNA) News Today—November 11, 2025: UBS Sees 2026 Upside, Redburn Cuts PT to $36, Bernstein Stays Market Perform After Cost Cuts - ts2.tech
Moderna's Cost-Cutting, Pipeline Catalysts Set Stage for 2026 Upside, UBS Says - MarketScreener
Moderna Announces First Made-in-Canada mRNA Vaccines Delivered to Canadian Provinces and Territories - The Commercial Appeal
Moderna to Host Investor Event – Analyst Day - The Augusta Chronicle
Moderna (NASDAQ:MRNA) Price Target Cut to $21.00 by Analysts at Bank of America - MarketBeat
Rothschild & Co Redburn Adjusts Price Target on Moderna to $36 From $53, Maintains Neutral Rating - MarketScreener
Q3 Rundown: Moderna (NASDAQ:MRNA) Vs Other Therapeutics Stocks - The Globe and Mail
Moderna Reports Third Quarter 2025 Financial Results and Provides Business Updates - The Marion Star
Is it too late to sell Moderna Inc.2025 Support & Resistance & Stock Market Timing Techniques - newser.com
Moderna (NASDAQ:MRNA) Nasdaq Composite ETF Shapes MedTech Rise - Kalkine Media
What’s next for Moderna Inc. stock priceEarnings Beat & Target Return Focused Picks - newser.com
B of A Securities Maintains Moderna (MRNA) Underperform Recommendation - Nasdaq
Telemark Asset Management Builds Position in Beaten-Down Biotech Stock. - The Globe and Mail
Palmetto Grain Brokerage - Palmetto Grain Brokerage
Trump administration cancels Moderna contract to fight bird flu and other viruses - news8000.com
What Are Wall Street Analysts’ Target Price for Moderna Stock? - Barchart.com
MRNA: B of A Securities Lowers Price Target Amidst Underperform Rating | MRNA Stock News - GuruFocus
2.08%
0.19%
자본화:
|
볼륨(24시간):